정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2235 | Completed | Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients | Helminthiasis | Drug: Ivermectin Drug: Albendazole |
Phase 2 | Alejandro Krolewiecki, Brock University, Universidad Nacional del Centro de la Provincia de Buenos Aires, Universidad Nacional Autonoma de Honduras | OTHER | 176 | All | 2 Years ~ 14 Years | IIET, Oran, Salta, Argentina Universidad Autonoma de Honduras, Tegucigalpa, Honduras |
2234 | Terminated | ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease | COVID-19 | Drug: Hydroxychloroquine | Phase 3 | Dr. Michael Hill, Alberta Health Services, University of Alberta, University of Calgary, Calgary Health Trust, Alberta Innovates Health Solutions, Government of Alberta | OTHER | 148 | All | 18 Years | University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada University of Alberta, Edmonton, Alberta, Canada |
2233 | Recruiting | Allergy and COVID-19 Vaccines | Vaccine Reaction | Biological: COVID-19 Vaccines | Phase 3 | Assistance Publique - Hopitaux de Paris | OTHER | 120 | All | 18 Years | Tenon Hospital APHP dermatology and allergology department, Paris, France |
2232 | Active, not recruiting | Allocetra-OTS in COVID-19 | COVID-19 | Biological: Allocetra-OTS | Phase 1 | Hadassah Medical Organization | OTHER | 5 | All | 18 Years ~ 80 Years | Hadassah Medical Center, Jerusalem, Israel |
2231 | Recruiting | Allocetra-OTS in COVID-19, Phase II | Covid19 | Biological: Allocetra-OTS | Phase 2 | Hadassah Medical Organization, Barzilai Medical Center, Tel-Aviv Sourasky Medical Center | OTHER | 24 | All | 18 Years ~ 80 Years | Barzilai Medical Center, Ashkelon, Israel Hadassah Medical Center, Jerusalem, Israel Tel Aviv Sourasky Medical Center, Tel Aviv, Israel |
2230 | Recruiting | Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19 | COVID-19 Pneumonia | Biological: DVX201 | Phase 1 | Deverra Therapeutics, Inc., Fred Hutchinson Cancer Research Center | INDUSTRY | 18 | All | 18 Years ~ 80 Years | Fred Hutch/University of Washington Medical Center, Seattle, Washington, United States |
2229 | Recruiting | Amantadine for COVID-19 | Covid19 | Drug: Amantadine Drug: Lactose monohydrate |
Phase 3 | Copenhagen University Hospital, Hvidovre, University of Copenhagen | OTHER | 226 | All | 18 Years | Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark |